author-photo

Jayesh Desai

Peter MacCallum Cancer Centre
Royal Melbourne Hospital
Walter and Eliza Hall Institute of Medical Research

301

Papers

13617

Citations

Citation Trend

Filter By

Papers (219) Sort By

Journal Conference Others

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

2021 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (1)
P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma

2021
Show All
- Source
- Cite
- Save
Citations (0)
Comparing survival outcomes for advanced cancer patients who access comprehensive genomic sequencing using a registry-based synthetic control arm.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Author response for "Determination of Protein Concentration in Downstream Biomanufacturing Processes by In‐Line Index of Refraction"

2021 Biotechnology Progress
Show All
- Source
- Cite
- Save
Citations (0)
Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases

2021 Current Oncology
Show All
- Source
- Cite
- Save
Citations (0)
BREAKWATER: Randomized phase 3 study of encorafenib (enco) cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)